Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

2026 Back of the Eye Disorders Market Research Report (2nd Edition): A Development Pipeline Consisting of ~690 Approved or Clinical-Stage Therapeutic Candidates

globenewswire.com
KODK Kodiak Sciences is mentioned as having a promising Phase III candidate (KSI-501) for back of the eye disorders, indicating potential future growth. OTLK Outlook Therapeutics is mentioned as having a promising Phase III candidate (ONS-5010) for back of the eye disorders, indicating potential future growth. ALDX Aldeyra Therapeutics is mentioned as having a promising Phase III candidate (ADX-2191) for back of the eye disorders, indicating potential future growth. OCUL Ocular Therapeutix is mentioned as having a promising Phase III candidate (OTX-TKI) for back of the eye disorders, indicating potential future growth. REGN Regeneron Pharmaceuticals is listed as a prominent company operating in the back of the eye disorders market, suggesting its involvement in a growing sector. ABBV AbbVie is listed as a prominent company operating in the back of the eye disorders market, suggesting its involvement in a growing sector. NVS Novartis is listed as a prominent company operating in the back of the eye disorders market, suggesting its involvement in a growing sector. BHC Bausch + Lomb (part of BHC) is mentioned for its acquisition of Whitecap Biosciences, indicating strategic moves within the glaucoma and geographic atrophy therapy space. SUN Sun Pharma is listed as a prominent company operating in the back of the eye disorders market, suggesting its involvement in a growing sector.

2026 Back of the Eye Disorders Market Research Report (2nd Edition): A Development Pipeline Consisting of ~690 Approved or Clinical-Stage Therapeutic Candidates Dublin, Sept. 03, 2026 (GLOBE NEWSWIRE) -- The "Back of the Eye Disorders Market (2nd Edition) by Scale of Operation, Type of Molecule, Target Indication, Geographical Regions, Key Players, and Sales Forecast of Commercialized Drugs - Trends and Forecast Till 2035" has been added to ResearchAndMarkets.com's offering.

The global back of the eye disorders market is projected to grow from USD 18.28 billion in 2026 to USD 41.56 billion by 2035, representing a compound annual growth rate of 9.6% during the forecast period. Market expansion is being supported by the increasing prevalence of retinal diseases, a growing geriatric population, rising diabetes incidence, and continued innovation in ophthalmic therapeutics and ocular drug delivery technologies.

Market Growth and Emerging Treatment Trends

Therapies for posterior segment disorders address serious retinal conditions such as age-related macular degeneration, diabetic retinopathy, diabetic macular edema, retinal vein occlusion, geographic atrophy, glaucoma, and uveitic macular edema. The treatment landscape increasingly incorporates advanced biologics, next-generation anti-VEGF therapies, bispecific antibodies, sustained-release formulations, port delivery systems, and gene and cell therapies.

These innovations are intended to improve treatment durability, preserve retinal function, and reduce the frequency of intravitreal injections. Demand is also being reinforced by advances in high-resolution optical coherence tomography, wider retinal screening programs, and improved disease awareness, which support earlier diagnosis and intervention.

Nearly 200 million people worldwide are currently affected by age-related macular degeneration, and this population is expected to approach 300 million by 2040. Combined with the growing global burden of diabetes, this trend is creating sustained demand for effective long-term retinal disease management.

Key Back of the Eye Disorders Market Insights

Promising Phase III candidates include KSI-501 from Kodiak Sciences, OVX-001 from Ocuvex Therapeutics, ADX-2191 from Aldeyra Therapeutics, ONS-5010 from Outlook Therapeutics, and OTX-TKI from Ocular Therapeutix. Successful development and regulatory approval of these candidates could broaden available treatment options and support future market growth.

Diabetic Macular Edema Leads by Target Indication

Diabetic macular edema accounts for nearly 40% of the global back of the eye disorders market in 2026, making it the largest therapeutic segment. Its leadership is supported by the rising prevalence of diabetes and continued demand for established therapies, including Eylea, Eylea HD, Lumitin, Lucentis, and Vabysmo. OCS-01, an investigational therapy from Oculis, may further expand the treatment landscape following successful Phase III development and regulatory review.

Uveitic macular edema is projected to register the highest growth rate during the forecast period. Key contributing factors include unmet clinical needs, increasing adoption of long-acting intravitreal implants and targeted biologics, and improving reimbursement conditions.

Regional Market Outlook

North America is expected to maintain its leadership and account for approximately 60% of the global market by 2035. The region benefits from advanced research and manufacturing capabilities, strong academic and industry collaboration, active intellectual property development, and continued mergers and acquisitions. Bausch + Lomb's acquisition of Whitecap Biosciences illustrates the strategic emphasis on strengthening pipelines for glaucoma and geographic atrophy therapies.

Asia-Pacific is forecast to expand at a CAGR of 11.9%, driven by increasing healthcare expenditure, improving access to advanced ophthalmic treatments, growing retinal disease awareness, and an expanding patient population. Regional pharmaceutical companies, including Astellas Pharma and Otsuka Pharmaceutical, are contributing to the development of innovative posterior segment therapies.

Market Challenges

Growth may be constrained by physiological barriers that limit drug penetration, dependence on invasive administration methods, treatment fatigue, and risks associated with repeated intravitreal injections. The chronic nature of retinal disorders also creates substantial clinical and economic burdens for patients and healthcare providers.

Additional challenges include the high cost of biologics, gene therapies, and sustained-release platforms; reimbursement limitations; variable treatment response; restricted access to specialist retinal care; lengthy clinical development timelines; stringent regulatory requirements; and complex manufacturing processes. Addressing affordability, accessibility, and treatment adherence will be critical to realizing the market's full potential.

Competitive Landscape

Prominent companies operating in the back of the eye disorders market include AbbVie, Astellas Pharma, Bausch + Lomb, Chiesi, Genentech, Novartis, Otsuka Pharmaceutical, Regeneron Pharmaceuticals, Roche, and Sun Pharma. Competition is expected to intensify as developers pursue longer-acting therapies, differentiated mechanisms of action, and advanced delivery platforms.

Report Scope

The market report evaluates opportunities by scale of operation, molecule type, target indication, and geography. It includes analysis of clinical- and commercial-scale products; biologics and small molecules; and major indications such as diabetic macular edema, wet age-related macular degeneration, diabetic retinopathy, glaucoma, geographic atrophy, uveal melanoma, retinal vein occlusion, choroidal neovascularization, and inherited retinal disorders.

Geographic coverage includes North America, Europe, Asia-Pacific, the Middle East and North Africa, and Latin America. The research also examines market drivers, restraints, opportunities, competitive positioning, company portfolios, development pipelines, routes of administration, dosing frequency, mechanisms of action, regulatory designations, and recent industry developments.

The report provides revenue forecasts, segment-level opportunity analysis, company profiles, market competitiveness assessments, and strategic insights designed to support pharmaceutical companies, biotechnology developers, investors, healthcare organizations, and new market entrants in informed decision-making.

Key Attributes

A selection of companies mentioned in this report includes, but is not limited to:

For more information about this report visit https://www.researchandmarkets.com/r/19yo5k

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Attachment